Parallel Advisors’s Antares Pharma, Inc. ATRS Stock Holding History

Parallel Advisors’s Portfolio ATRS Stock Details ATRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-1	Closed	–	–	2490
2019 Q1	$0	Buy	+1	New	+$3	﹤0.01%	2439

Other funds holding ATRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

CAM

Cortina Asset Management Milwaukee, Wisconsin $1.62B AUM 15.44% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Parallel Advisors's ATRS Position: Q2 2019 in Review

Parallel Advisors sold out of Antares Pharma, Inc. (ATRS) in Q2 2019, closing a stake of 1 share.

Parallel Advisors first reported a position in ATRS in Q1 2019 and held it in 1 quarter. The position peaked at $0 in Q1 2019. 127 funds tracked by Wall St. Rank hold ATRS as of Q2 2019.

Parallel Advisors reported no remaining Antares Pharma, Inc. position as of Q2 2019 after selling out during the quarter.
Parallel Advisors sold 1 Antares Pharma, Inc. share in Q2 2019.
Parallel Advisors first reported a position in Antares Pharma, Inc. in Q1 2019 and held it in 1 quarter.
Parallel Advisors's Antares Pharma, Inc. position peaked at $0 in Q1 2019.
127 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2019.

Based on Parallel Advisors's 13F filing for Q2 2019, filed 5 Aug 2019.